Madrigal Pharmaceuticals/$MDGL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Ticker
$MDGL
Sector
Primary listing
Employees
915
Headquarters
Website
MDGL Metrics
BasicAdvanced
$11bn
-
-$13.65
-1.05
-
Price and volume
Market cap
$11bn
Beta
-1.05
52-week high
$615.00
52-week low
$275.00
Average daily volume
285k
Financial strength
Current ratio
3.495
Quick ratio
2.972
Long term debt to equity
63.596
Total debt to equity
63.908
Interest coverage (TTM)
-11.68%
Profitability
EBITDA (TTM)
-311.996
Gross margin (TTM)
93.07%
Net profit margin (TTM)
-27.32%
Operating margin (TTM)
-27.68%
Revenue per employee (TTM)
$1,240,000
Management effectiveness
Return on assets (TTM)
-17.62%
Return on equity (TTM)
-49.35%
Valuation
Price to revenue (TTM)
9.435
Price to book
19.98
Price to tangible book (TTM)
20.25
Price to free cash flow (TTM)
-38.798
Free cash flow yield (TTM)
-2.58%
Free cash flow per share (TTM)
-12.148
Growth
Revenue change (TTM)
256.82%
Earnings per share change (TTM)
-18.81%
3-year earnings per share growth (CAGR)
-8.95%
10-year earnings per share growth (CAGR)
7.72%
What the Analysts think about MDGL
Analyst ratings (Buy, Hold, Sell) for Madrigal Pharmaceuticals stock.
MDGL Financial Performance
Revenues and expenses
MDGL Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs